Navigation Links
In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
Date:2/20/2009

SANTA MONICA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, provided details of the Company's special shareholder meeting in March.

The complete interview is available at: http://www.stoxrox.com/cbai-2-18-09-e.mp3

In the interview, Mr. Schissler explains why the Company is asking for an increase in authorized shares. He explains that authorized is "vastly different from outstanding" and the Company currently has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.

"Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny," Mr. Schissler said. Asked why Cord Blood America is asking for such a large increase in authorized shares, the Company's founder said "this is a time-consuming, costly process and we only want to do it once in the Company's history."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

        CONTACT:
        Paul Knopick
        E & E Communications
        949/707-5365
        pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
2. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
3. EntreMed to Present at the New York Society of Security Analysts Industry Conference
4. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
5. Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts
6. Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts
7. Global Agricultural and Environmental Diagnostics Market to Reach $2.4 Billion by 2012, According to New Report by Global Industry Analysts
8. World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
9. World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.
10. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
11. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
(Date:1/19/2017)... ... 18, 2017 , ... LabRoots , the leading provider ... world, was today awarded the "Best Science & Technology Social Networking Service 2016" ... decided upon by a dedicated team of researchers and analysts. , The 2016 ...
(Date:1/19/2017)... , Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: ... personalized immune therapies for operable and inoperable solid tumor ... Chief Technical Officer of NW Bio, will present at ... 2017, at the Hyatt Regency Hotel in ... chair the session entitled "New Therapeutic Approaches – Expanding ...
(Date:1/18/2017)... , January 18, 2017 According to a new market ... Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research ... to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
Breaking Biology News(10 mins):